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Abstract
Background
Chloroquine combined with primaquine has been the recommended antimalarial treatment
of Plasmodium vivaxmalaria infections for six decades but the efficacy of this treatment reg-
imen is threatened by chloroquine resistance (CQR). Single nucleotide polymorphisms
(SNPs) in the multidrug resistance gene, Pvmdr1 are putative determinants of CQR but the
extent of their emergence at population level remains to be explored.
Objective
In this study we describe the prevalence of SNPs in the Pvmdr1 among samples collected
in seven P. vivax endemic countries and we looked for molecular evidence of drug selection
by characterising polymorphism at microsatellite (MS) loci flanking the Pvmdr1 gene.
Methods
We examined the prevalence of SNPs in the Pvmdr1 gene among 267 samples collected
from Pakistan, Afghanistan, Sri Lanka, Nepal, Sudan, São Tomé and Ecuador. We mea-
sured and diversity in four microsatellite (MS) markers flanking the Pvmdr1 gene to look evi-
dence of selection on mutant alleles.
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Results
SNP polymorphism in the Pvmdr1 gene was largely confined to codons T958M, Y976F and
F1076L. Only 2.4% of samples were wildtype at all three codons (TYF, n = 5), 13.3% (n =
28) of the samples were single mutant MYF, 63.0% of samples (n = 133) were double
mutant MYL, and 21.3% (n = 45) were triple mutant MFL. Clear geographic differences in
the prevalence of these Pvmdrmutation combinations were observed.
Significant linkage disequilibrium (LD) between Pvmdr1 and MS alleles was found in
populations sampled in Ecuador, Nepal and Sri Lanka, while significant LD between
Pvmdr1 and the combined 4 MS locus haplotype was only seen in Ecuador and Sri Lanka.
When combining the 5 loci, high level diversity, measured as expected heterozygosity (He),
was seen in the complete sample set (He = 0.99), while He estimates for individual loci ran-
ged from 0.00–0.93. Although Pvmdr1 haplotypes were not consistently associated with
specific flanking MS alleles, there was significant differentiation between geographic sites
which could indicate directional selection through local drug pressure.
Conclusions
Our observations suggest that Pvmdr1mutations emerged independently on multiple occa-
sions even within the same population. In Sri Lanka population analysis at multiple sites
showed evidence of local selection and geographical dispersal of Pvmdr1mutations
between sites.
Author Summary
Chloroquine combined with primaquine has been the recommended antimalarial treat-
ment for Plasmodium vivaxmalaria infections for sixty years but the efficacy of this treat-
ment regimen is threatened by chloroquine resistance. In this study we describe the
prevalence of mutations in the P. vivax gene, Pvmdr1 among samples collected in seven
endemic countries. The mutations are thought to be associated with chloroquine resis-
tance and here we looked for evidence of drug selection by characterising polymorphism
in DNA repeat regions (microsatellite (MS) loci) flanking the Pvmdr1 gene. Mutations in
the Pvmdr1 gene were mainly identified at codons T958M, Y976F and F1076L. Just 2.4%
of samples were wildtype at all three codons, while 63% were single mutants (MYF). Clear
geographic differences in the prevalence of these Pvmdrmutation combinations were
observed. At the flanking MS loci, we found high levels of diversity, and significant differ-
entiation between geographic sites. This pattern of variation could indicate directional
selection through local drug pressure. In summary, our observations suggest that Pvmdr1
mutations and thus, chloroquine resistance has emerged independently on multiple occa-
sions even within the same population.
Introduction
Malaria is one of the world’s leading causes of mortality and morbidity. Since late in the 1940s
the antimalarial drug chloroquine (CQ) has been the primary chemotherapeutic for prophy-
laxis and treatment of malaria because of its good safety profile, low cost and high efficacy
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against the blood stages of CQ sensitive (CQS) Plasmodium parasites, causing the disease.
Since the 1950`s, CQ treatment of P. vivax infections has been combined with the hypnozoito-
cidal drug primaquine (PQ) for clearance of the latent P. vivax liver stages, responsible for later
relapses of the disease [1–3]. Compared to P. falciparum, development of CQ resistance (CQR)
in P. vivax has been relatively slow with the first reports emerging in 1989 in Papua New
Guinea (PNG) [4]. Since then, CQR has spread and today it is considered to be present in
vivax-malaria endemic countries all over the world (reviewed in [5] and more recently in [6]).
Development of CQR has been slower in P. vivax than P. falciparum and this is sometimes
attributed to the use of combined treatment (CQ with PQ), where PQ acts synergistically with
CQ against CQR parasites [7]. It is also proposed that CQR in P. vivax has a different CQR
mechanism than P. falciparum [8].
Knowledge of the mode of action of CQR in P. vivax is limited. In P. falciparum, reduced
CQ sensitivity is strongly associated with single nucleotide polymorphisms (SNPs) in the chlo-
roquine resistance transporter-gene, Pfcrt [9;10]. However, studies of the Pfcrt orthologue in P.
vivax, Pvcg10, have not been able to find an association to CQR [8;11]. In P. falciparum is the
P-glycoprotein–like molecule Pgh-1 encoded by Pfmdr1, is also associated with CQR though it
may only modulate the effects of the Pfcrt gene [12;13]. In 2005, Brega et al. characterized the
mdr-like gene Pvmdr1 in P. vivax isolates [14], and evidence suggests that SNPs in the Pvmdr1
gene are a possible genetic determinant of CQR [11;14;15]. Cross-species comparisons led the
focus in P. vivax to be primarily on themdr-codons orthologous to codons implicated in P. fal-
ciparum CQR namely 86, 184, 1034, 1042 and 1246 [14;16]. However codons 91 and 189
which are homologous to codons 86 and 184 in P. falciparum [14;17] and codons 1071 and
1079 which are homologous to codons 1034 and 1042 in P. falciparum [14] are rarely polymor-
phic in Pvmdr1 Instead SNPs at codons, 976 and 1076, have been detected multiple times
[11;14;15;18;19]. Suwanarusk et al. observed an association between the Y976F mutation and
increased CQ IC50 in samples from Thailand and Papua province of Indonesia, and stated that
the Y976F mutation is a useful tool to indicate foci of chloroquine resistance [11]. Others detect
the mutations, but doubt their association with CQR [15;18;20–23].
Studies of P. falciparum drug resistance loci have used flanking microsatellite (MS) variation
to describe selective sweeps around Pfdhfr [24] and Pfdhps [25] and Pfcrt [26]. This approach
has revealed lineages of drug resistance mutant alleles which are derived from a single emer-
gence event. Notably, in P. falciparum some resistance lineages were found to have spread
across vast geographical distances [26;27]. When the same approach was repeated antifolate
drug targets in P. vivax Pvdhfr [28] and Pvdhps [29] contrasting results were found. In Pvdhfr
and Pvdhps there was evidence of multiple independent mutation events with little selective
sweep around mutant alleles at those loci. This result may reflect the limited antifolate drug
selection pressure that has historically been applied to P. vivax, or it may point to differences in
transmission and selection dynamics in the two species. In this study we looked for evidence of
drug selection on the CQR candidate Pvmdr using MS flanking the Pvmdr1 gene.
We analysed samples collected from Pakistan, Afghanistan, Sri Lanka, Nepal, Sudan, São
Tomé and Ecuador. In Pakistan approximately 83% of the malaria cases are caused by P. vivax
and in Afghanistan, 95% are P. vivax. In both countries P. vivax infections are still being treated
with CQ + PQ [30]. Around 83% of reported malaria infections in Sri Lanka were caused by P.
vivax and CQ with PQ were still efficient and recommended treatment of P. vivax infections
on the island until autochthonous cases of both P. falciparum and P. vivax in Sri Lanka fell to
zero [30]. In Nepal 88% of the malaria cases are caused by P. vivax and treated with CQ + PQ
[30]. In Ecuador, P. vivax accounts for 86% of all malaria infections and is treated with CQ
+ PQ [30]. To the best of our knowledge no cases of CQR have been reported from either
Nepal or Ecuador. Only, 5% of the malaria infections in Sudan are caused by P. vivax and these
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are treated with artemether-lumefantrine + PQ [30]. No reports of P. vivax CQR have been
published from Sudan. Falciparum malaria is the main cause of malaria in São Tomé and no
recommendations are provided regarding treatment of P. vivax [30].
The objectives of the present study were to 1) Determine the diversity of SNPs in the
Pvmdr1 gene, a putative marker of CQR, in P. vivax samples collected from Pakistan, Afghani-
stan, Sri Lanka, Nepal, Ecuador, Sudan and São Tomé and 2) Characterise flanking MS varia-
tion and use this to explore the evolutionary origin of Pvmdrmutations.
Methods
Sample collection and description of collection sites
The total number of P. vivax samples analysed in this study was 267. The samples originated
from 7 countries: Pakistan (n = 36), Afghanistan (n = 13), Nepal (n = 55), Sri Lanka (n = 136),
Ecuador (n = 17), São Tomé (n = 4) and Sudan (n = 6). The samples were all (with the excep-
tion of Sao Tomé, and Sudan) derived from larger sets of PCR positive samples and the subset
selected by computer randomisation. The DNA from a total of 263 P. vivax samples selected
were already extracted as part of a P. vivaxmicrosatellite study described previously [31].
Pakistan and Afghanistan: Forty-nine samples from a cluster of neighbouring sites in Paki-
stan and Afghanistan were analysed. Thirty-six were from Pakistan (n = 36); Ashaghroo refu-
gee camp in Adizai from 2003 (n = 10), Adizai Refugee Village in Peshawar from 2004–2005
(n = 3) sampled as part of another study [32] and lastly Adizai, Baghicha and Khagan villages
located near Peshawar 2005–2006 (n = 23) described in [33]. Thirteen samples were from
Afghanistan collected at the Malaria Reference Center in Jalalabad in 2004–2005 [32]. The
samples from all these sites were grouped together because of similar study designs and close
geographical distance between the sites.
Sri Lanka: The samples from Sri Lanka were collected in 9 malaria endemic districts during
2002–2007, see [34]. For this study, the samples were divided into 9 groups of districts, where
after randomised computerisation was used to select samples from each district (N = 136).
Nepal: Samples from two separate studies in Nepal were grouped together. Thirty-eight
samples collected in 2009–2010 from the districts of Jhapa (N = 34) and Banke, Chitwan and
Dang (N = 5) have been previously described in [35]. The other study collected samples in the
districts of Kanchanpur (N = 5) and Jhapa (N = 12) in 2005–2006 as a part of a cross-sectional
prevalence survey estimating the malaria burden and risk behaviour in two endemic districts of
Nepal (S. Hewitt, personal communication). The Kanchanpur samples were grouped with
Banke, Chitwan and Dang.
Ecuador: Twenty-one P. vivax samples were collected from 2007–2009 in the Province of
Sucumbíos through the network of laboratories of the Ministry of Health.
Sudan: Six P. vivax samples from Sudan were collected in the village of Asar in Gedaref state
in 2006 as a part of an artemether-lumefantrine efficacy trial community based survey [36].
The amount of available P. vivax DNA was small, and only limited analysis was possible.
São Tomé: The island São Tomé is a part of the Democratic Republic of São Tomé and Prín-
cipe in the western equatorial coast of Central Africa. Four samples were available. As with the
samples from Sudan, limited analysis was possible because only a small amount of extracted
DNA-solution was available.
Amplification and sequence analysis of the Pvmdr1 gene
A fragment spanning nucleotide 2596 and 3532 (amino acids 865–1177) of the Pvmdr1 gene
and was amplified using semi-nested primers Pvmdr1-4F [11], Pvmdr1-AS and Pvmdr1-S
[14]. Primer sequences are shown in Table 1. Cycling conditions were as follows: 94°C for 15
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min, followed by 30 cycles of 94°C for 30 s, 55°C for 1 min, and 72°C for 1 min, and finally
72°C for 10 min. The amplified Pvmdr1 fragments were sequenced on an ABI Prism 377 (Per-
kin-Elmer) using the Big Dye terminator reaction mix (Perkin-Elmer). After sequencing, the
individual haplotypes were aligned and analysed by use of the DNASTAR-Lasergene software.
Identification of microsatellites
The Pvmdr1 gene is located on chromosome 10, and sequences flanking the gene were screened
for suitable microsatellite marker loci in the Salvador-1 (Sal-1) reference strain (accessed
through the European Bioinformatics Institute homepage (www.ncbi.nlm.nih.gov/). Multiple
repeats were identified using the software Tandem Repeats Finder [37] and semi-nested prim-
ers designed (Table 1). The primary reaction comprised of 1μl template, 0.5 unit Taq polymer-
ase, 1.1μl Thermopol Reaction buffer (New England Biolabs Inc, Glostrup, Denmark), and
0.4μM dNTPs, 0.1μM of forward (F) and reverse primers (R) with cycling conditions as fol-
lows; 2 min at 94°C and then 25 repeated cycles of 30 s at 94°C, 30 s at 42°C, 30 s at 40°C and
40 s at 65°C followed by 2 min at 65°C and a minimum of 10 min at 15°C. In the secondary
PCR, the same concentrations of reagents were added, but with 0.15μM of reverse primers (R)
and fluorescent-labelled inverse primers (I). The cycling conditions were initiated with 2 min
at 94°C followed by 25 repeated cycles of 20 s at 94°C, 20 s at 45°C, 30 s at 65°C, and finished
with 2 min at 65°C and 10 min at 15°C.
A panel of four MS were selected for further analysis on the basis of their successful amplifi-
cation and were named according to their distance to the Pvmdr1 gene: m9.5 (9,489 bp down-
stream of Pvmdr1), m10.1 (10,120 bp downstream), m10.4 (10,420 upstream) and m43.1
(43,168 bp upstream), (Fig 1). PCR amplified fragments were run with LIZ-500 size standard
on an ABI 3730XL genetic analyzer (Applied Biosystems), and analysed using the GeneMapper
software (Applied Biosystems). Samples that were negative by PCR were repeat amplified with
2μl template in the first PCR.
Table 1. Primers for amplification and sequencing of the Pvmdr1 gene and four flanking polymorphic repeat regions.
Locus Primer Use Sequence (5’-3’)
Pvmdr1 Pvmdr1-4F 1st PCR (F) CCCTCTACATCTTAGTCATCG
Pvmdr1-AS 1st and 2nd PCR (R) ACGTTTGGTCTGGACAAGTATC
Pvmdr1-S 2nd PCR (F) ATAGTCATGCCCCAGGATTG
MS Repeat Size range
m9.5 AAT 199–207 m9.5F 1st and 2nd PCR (F) TATGTGGAGAAGGGGAAACG
m9.5R 1st PCR, (R) TCTCGTTATTGCTCGCCACT
m9.5I-FAM 2nd PCR, (R) FAM-TGCCACATTCATTCTTGAGC
m10.1 A, AT 266–322 m10.1F 1st and 2nd PCR (F) GCTGCGCCTATAAAAGTTCG
m10.1R 1st PCR, (R) GACTTGGAATTCCCACTGCTA
m10.1I-FAM 2nd PCR, (R) FAM-GCACTCCATTGTTTCGACTG
m10.4 GCATTTAT 230–308 m10.4 1st and 2nd PCR (F) GCAGTACTTTGTTCCTCCAC
m10.4R 1st PCR, (R) TCAAACTCAAACGCCTTGC
m10.4I-FAM 2nd PCR, (R) FAM-CAAAGGGGGAAATAAAAATTCA
m43.1 TA, GT 419–472 m43.1F 1st and 2nd PCR (F) GCCATGTAAGCCAGAAGTGC
m43.1R 1st PCR, (R) GTTAAAACGAGAAGGCACATAGG
m43.1-I-FAM 2nd PCR, (R) FAM-CGTGTGCATACGCAGACATA
(F): forward primer, (R): reverse primer. MS: Microsatellites. FAM: primer labeled with FAM in 5’-end.
doi:10.1371/journal.pntd.0004196.t001
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The number and length of the repeats in each of the four MS is shown in Table 1. In the
cases where multiple ( 2) microsatellite alleles were detected in a single sample the major/
predominant allele chosen, (‘predominant’ is defined by the electropherogram peak height
which had to be twice that of the minor allele).
Data analysis
Linkage disequilibrium (LD) was calculated to test for a non-random association of Pvmdr1
allele and the MS alleles. Only the non-mixed samples were used in the calculations. LD was
measured by the formula D' = D/Dmax, where D equals derivation of random association
between alleles at different loci, and D’ measures D standardized by the maximum value
(Dmax), given the observed allele frequencies. LD values range from -1 to +1, where the value
+1 refers to a complete non-random association between the alleles. Values of gene diversity
were calculated by expected heterozygosity by the formula He = (n/[n-1])(1-∑pi
2), by use of the
Arlequin software [38], where He is expected heterozygosity, n the number of samples, and pi
the frequency of the i-th allele in the sample set.
Ethical statement
Clearance for analysis of Plasmodium genes were approved by London School of Hygiene
Tropical Medicine and Hygiene Ethics Board, locally by Bioethics Committee, Pakistan Medi-
cal Research Council and Directorate of Public Health, Jalalabad, Nangahar, Comitee de Bioe-
tica Universidad San Francisco de Quito, Committee on Research and Ethical Review at the
Faculty of Medicine, Peradeniya, Kandy and the Nepal Health Research Council. All data ana-
lysed were anonymized.
Results
Analysis of the Pvmdr1 gene
The analysis of Pvmdr1 in 39 samples from Nepal was previously published [35]. Of the
remaining 228 samples, sequencing was successful in 173 (75.9%); Pakistan (n = 24), Nepal
(n = 4), Sri Lanka (n = 120), São Tomé (n = 3), Sudan (n = 4) and Ecuador (n = 17). Combined
with the 39 samples from Nepal, 212 Pvmdr1 sequence fragments were available for further
analysis (Table 2, Fig 2).
SNP variation in fragment 2 was largely confined to three codons; T958M (ACG!ATG),
Y976F (TAC!TTC) and F1076L (TTT!CTT), (Fig 1). Three novel SNPs were detected in
two samples from the Jhapa district in Nepal. These were sequenced twice to confirm the
results. One of the samples carried a SNP at c1080 (S1080N, AGT!AAT), while the other
Fig 1. The Pvmdr1 gene and the relative position of the chosenMS. The identified SNPs within Pvmdr1
and the two chosen MS downstream of the Pvmdr1 gene; m9.5 (9,489 bp downstream of Pvmdr1), m10.1
(10,120 bp downstream) and the two upstreamMS: m10.4 (10,420 upstream) and m43.1 (43,168 bp
upstream) are shown.
doi:10.1371/journal.pntd.0004196.g001
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sample possessed SNPs at c979 (F979S, TTT!TCT) and c980 (M980V, ATG!GTG)
(Table 3). These two samples and the SNPs were described by Ranjitkar et al. [35].
The substitutions at codons 958,976, and1076 were found in various configurations. TYF
(the wild-type) was found only in Ecuador in 5 of 17 samples (Fig 2, S1 Table). All the remain-
ing samples carried one of three mutant haplotypes, MYF (single mutant, T958M), MYL (dou-
ble mutant, T958M and F1076L) and MFL (triple mutant T958M, Y976F and F1076L). The
Fig 2. Pvmdr1 polymorphism in Plasmodium vivax samples collected at 8 geographical sites. Four Pvmdr1 alleles were detected in the study
abbreviated as TYF, MYF, MYL and MFL. The TYF wild-type is shown in blue, MYF (single mutant, T958M) in yellow, MYL (double mutant, T958M+F1076L)
in green, and MFL (triple mutant T958M+Y976F+F1076L) in red. The number of positive samples from each site is shown on the map in brackets, and the
number of alleles and percentage frequency overall are shown in the legend.
doi:10.1371/journal.pntd.0004196.g002
Table 2. Allelic diversity measured by expected heterozygosity (He).
Origin Pvmdr1 m9.5 m10.1 m10.4 m43.1 5-loci haplotype
Pakistan/Afghanistan 0.00 (1/24) 0.10 (2/20) 0.87 (8/17) 0.74 (6/39) 0.44 (2/29) 0.96 (9/11)
Nepal 0.32 (3/43) 0.56 (4/32) 0.93 (17/37) 0.82 (10/45) 0.40 (3/34) 1.00 (24/24)
Sri Lanka 0.54 (3/120) 0.34 (2/115) 0.82 (12/117) 0.82 (8/122) 0.47 (2/97) 0.97 (39/73)
Ecuador 0.44 (2/17) 0.00 (1/17) 0.68 (4/16) 0.68 (3/16) 0.49 (2/17) 0.83 (8/15)
Sao Tomé 0.00 (1/3) 0.00 (1/2) 1.00 (2/2) 0.00 (1/2) 1.00 (1/1) —-
Sudan 0.67 (2/4) 0.50 (2/4) 0.50 (2/4) 0.80 (3/5) 0.67 (2/3) 1.00 (1/1)
Mixed infections (%) —- 2 (1.1) 17 (8.7) 27 (11.8) 22 (12.2) 33 (26.4)
He (alleles/n) 0.54 (4/211) 0.43 (4/190) 0.90 (26/196) 0.83 (13/229) 0.47 (3/181) 0.99 (78/125)
He is shown for every locus and for the combined 5 locus haplotype at each study site. In brackets are the number of alleles detected and the sample
size.
The number (and percentage) of mixed infections detected at each locus is shown. The 5-loci haplotype calculations included samples with mixed
infection and used the majority allele for each locus.
doi:10.1371/journal.pntd.0004196.t002
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Table 3. Plasmodium vivax mdr1 alleles TYF, MYF and MYL and flankingmicrosatellite alleles.
Upstream Downstream
Origin 5-loci haplotypes number M43.1 M10.4 Pvmdr m9.5 m10.1 No. of samples with identical haplotype
Sal-1 —- 441 293 TYF 204 270 —-
Ecuador 1a 419 261 TYF 201 266 3
Nepal 2 437 266 MYF 204 298 1
Ecuador 3 437 266 MYF 201 300 1
Ecuador 4 437 266 MYF 201 301 1
Ecuador 5 437 266 MYF 201 303 1
Sri Lanka 6a 419 259 MYF 201 283 4
Sri Lanka 7 419 252 MYF 201 283 1
Ecuador 8 419 252 MYF 201 300 6
Ecuador 9 419 252 MYF 201 301 1
Nepal 10 419 233 MYL 204 308 1
Sri Lanka 13 419 252 MYL 204 282 4
Sri Lanka 14 419 252 MYL 204 289 1
Sri Lanka 15 419 252 MYL 204 300 1
Nepal 16 419 252 MYL 207 289 1
Sri Lanka 17 419 255 MYL 204 289 2
Nepal 18 419 259 MYL 201 289 1
Nepal 19 419 259 MYL 201 266 1
Nepal 20 419 259 MYL 201 290 1
Nepal 21 419 259 MYL 204 266 1
Nepalb 22 419 259 MYL 207 277 1
Pakistan 23 419 259 MYL 204 280 1
Nepal 24 419 259 MYL 204 289 1
Sri Lanka 25 419 259 MYL 204 297 1
Sri Lanka 26 419 259 MYL 204 298 1
Sri Lanka 27 419 259 MYL 204 299 3
Sri Lanka 28 419 259 MYL 204 300 1
Nepal 29 419 259 MYL 204 300 1
Nepalc 29 419 259 MYL 204 308 1
Sri Lanka 30 419 266 MYL 204 289 4
Sri Lanka 31 419 266 MYL 204 298 1
Sri Lanka 32 419 266 MYL 204 311 2
Pakistan 33 419 266 MYL 204 287 1
Nepal 34 419 266 MYL 204 297 1
Nepal 35 419 266 MYL 201 315 1
Nepal 36 419 266 MYL 201 289 1
Sri Lanka 37 419 270 MYL 204 289 4
Sri Lanka 38 419 270 MYL 204 299 1
Sudan 39 419 276 MYL 207 303 1
Sudan 40 419 308 MYL 204 293 1
Sri Lanka 41 437 252 MYL 201 297 1
Sri Lanka 42 437 252 MYL 204 297 5
Sri Lanka 43 437 255 MYL 204 311 1
Pakistan 44 437 255 MYL 204 283 1
Sri Lanka 45 437 259 MYL 201 289 1
Sri Lanka 46 437 259 MYL 204 289 1
(Continued)
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double mutant MYL was present in 63.0% of the samples (n = 133), the triple mutant MFL in
21.3% (n = 45), and the single mutant MYF in 13.3% (n = 28). Their relative abundance at the
different sites is shown in Fig 2. In Pakistan only the MYL double mutant haplotype was
detected, while the Ecuador samples (apart from the wild-type TYF) possessed the single
mutant MYF (n = 12). The Sudan P. vivax samples a mix of MYL (n = 2) and MFL (n = 2) hap-
lotypes were found, while the three samples from São Tomé all possessed the MFL haplotype
(Fig 2).
The heterozygosity of Pvmdr1measured as He is shown in Table 2. Measured over all sam-
ples He was 0.54. When divided by collection site, Sri Lanka was the most diverse (He = 0.54),
and Pakistan the least diverse (He = 0) with only one allele-the MYL haplotype. Although the
He value for Sudan was high (0.67), the sample size was small (n = 4), and the broad variation
in sample size between sites precluded further in-depth analysis of difference between the sites.
District level analysis was possible for Sri Lanka (Fig 3). In Sri Lanka, samples were collected
in 9 districts, and despite the small sample size per district, the distribution of alleles was simi-
lar at district level when compared to the pooled sample set, with a dominating MYL haplo-
type, followed by MFL and MYF. The exception was Kurunegala district where the MFL
haplotype was most common (n = 15), followed by the MYL haplotype (n = 5).
Analysis of the four microsatellites
Four MS from Pvmdr1 flanking genomic regions were genotyped in the 267 samples although
these were amplified with varying successes; for m9.5 (n = 190), m10.1 (n = 196), m10.4
(n = 229) and m43.1 (n = 181) alleles (Table 2). The m10.1 locus was the most polymorphic
with 26 alleles identified among 196 samples (He = 0.90), while m9.5 had 4 alleles, m10.4 had
Table 3. (Continued)
Upstream Downstream
Origin 5-loci haplotypes number M43.1 M10.4 Pvmdr m9.5 m10.1 No. of samples with identical haplotype
Nepal 47 437 259 MYL 201 286 1
Sri Lanka 48 437 266 MYL 204 303 1
Sri Lanka 49 437 270 MYL 204 289 2
Sri Lanka 50 419 244 MFL 204 305 1
Sri Lanka 51 419 252 MFL 204 283 1
Sri Lanka 52 419 255 MFL 201 283 1
Sri Lanka 53 419 255 MFL 204 297 1
Sri Lanka 54 419 266 MFL 204 299 4
Sri Lanka 55 419 270 MFL 204 289 1
Nepal 56 419 276 MFL 204 298 1
Sri Lanka 57a 437 255 MFL 204 291 5
Sri Lanka 58 437 270 MFL 204 299 1
The samples from Ecuador (n = 13), Nepal (n = 16), Pakistan (n = 3), Sri Lanka (n = 58) and Sudan (n = 2) a shown together with Sal-1 which is a wild-
type chloroquine sensitive haplotype (GenBank accession number AY571984.1). The number of samples per geographical origin, which possessed each
distinct haplotype are shown in the last column where there was more than one the row is highlighted dark gray: Excluded in the table are all the
polyclonal samples.
a5-loci haplotypes calculated to be in signiﬁcantly linkage disequilibrium (D` = 1, P<0.0001).
bA sample from Nepal contained two further mutations at c979 (F979S, TTT!TCT) and c980 (M980V, ATG!GTG).
cThis sample from Nepal was also mutated at c1080 (S1080N, AGT!AAT).
doi:10.1371/journal.pntd.0004196.t003
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Fig 3. Genetic diversity of the Plasmodium vivax mdr1 gene in P. vivax samples collected at 9 malaria
endemic districts of Sri Lanka. Three different genotypes were detected in the samples from Sri Lanka
namedMYF(yellow), MYL(green) and MFL(red). MYF (single mutant, T958M), MYL (double mutant, T958M
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13 and m43.1 had 3 different alleles (Table 2, and S1 Table). The number of mixed samples
(those containing more than one allele) detected using each locus differed; only 1% were mixed
at the m9.5 locus, while 12% were mixed at the m43.3 locus. When combining all 5 loci, 26%
were mixed among 125 samples (Table 2).
The m10.1 locus had a mono-A-repeat as well as an AT dinucleotide repeat, and this was
reflected in the high number of different alleles (He = 0.90). Ecuador was an exception, only
possessing 4 different m10.1 alleles among the 16 positive samples (He = 0.68). Allele size varia-
tion is shown in S1 Table, the highest number of observed MS alleles were generally of interme-
diate size.
The combination of all 5 loci resulted in 57 different 5-loci haplotypes among the monoclo-
nal samples (Table 3) and 78 when majority alleles in the mixed genotype samples were
included. All 5-locus haplotypes differed from the CQS wild-type Sal-1 haplotype. The most
commonly observed 5-locus haplotype was detected in Ecuador (n = 6, haplotype number 8 in
Table 3). The other frequently observed 5-loci haplotypes were all from Sri Lanka. The distri-
bution of the Pvmdr1 5- locus haplotypes among the sub-populations sampled in Sri Lanka is
shown in Fig 4. A large number of haplotypes occurred only once and these are indicated by
grey segments in the pie charts. Haplotypes which occurred multiple times are indicated each
by a different colour. The sample collections with the greatest degree of haplotype sharing were
from Trincomalee and Anuradhapura (6 haplotypes) and Anuradhapura and Polonaruwa (5
haplotypes of which only 1 was found in Trincomalee). Other sites appear more isolated, for
instance all the haplotypes found in the district of Batticaloa were unique.
Unfortunately, the small amount of DNA-solution available from Sudan and São Tomé pre-
vented reanalysis of these samples, and no 5-loci haplotype from Sao Tomé could be created.
We tested for LD, between Pvmdr1 alleles and flanking MS alleles. Significant associations
are shown in S2 Table. Strong linkage associations were seen in Ecuador where MS alleles
occurred in association with the MYF single mutant allele and also with the wildtype allele
TYF. Other population level LD associations were observed in Sri Lanka, and Nepal. In each
case different MS alleles were associated with the Pvmdr1 allele. When the 4 MS loci were com-
bined, significant LD between certain 4-loci haplotypes and either the TYF, MYF or MFL hap-
lotypes was found in Ecuador and Sri Lanka, (S2 Table). When samples from all sites were
pooled the LD analysis found significant associations of MS alleles with TYF and MFL which
are likely attributable to admixture.
Discussion
The aim of this study was to characterise SNPs in the Pvmdr1 gene, to examine whether the
putative CQR mutations have one, few or many origins, and to determine whether there has
been geographical spread of certain Pvmdr1 haplotypes. SNPs were found at three codons,
T958M, Y976F and F1076L among 267 samples from Pakistan, Nepal, Sri Lanka, Ecuador,
Sudan and São Tomé. Polymorphism in the last two codons has been described in multiple
studies [11;14;15;18;19;22;23], but the high prevalence of 958M which we observed (206/211,
97.6%) was surprising since this SNP has only been mentioned in two earlier studies; in Mada-
gascar (with a 100% fixation of the 958M) [18] and in a few samples from Indonesia and Brazil
[39]. Besides these studies, all others either report the presence of the wild-type T958 allele, or
do not mention the locus [11;20–23]. Since the 958Mmutation was present in countries with
both high and low level of reported CQR over a wide time span, we hypothesize that the
and F1076L) and MFL (triple mutant). The number of positive samples from each district is mentioned in
brackets.
doi:10.1371/journal.pntd.0004196.g003
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T958M is an allelic variant of the wildtype and most likely not associated with CQR. In the
present study the T958 wild-type was only detected in Ecuador. It is also seen in the Sal-1 refer-
ence sample which originates from El Salvador, so it is possible this allele might be a character-
istic of American samples while the 958M is characteristic of Asia and Africa.
Rare mutations, F979S (TTT!TCT), M980V (ATG!GTG) and S1080N (AGT!AAT)
were found in two samples from the Jhapa district of Nepal, both possessing the MYL double
mutant Pvmdr1 haplotype (Table 3); One of these samples was mutated at codon 1080 while
the other was mutated at codon 979 and codon 980. These results have been previously pub-
lished by Ranjitkar in 2011 [35]. Thus, in total only five Pvmdr1 SNPs were detected which was
an unexpected result. Orjuela-Sanchez et al. (2009) [23] reported up to 24 Pvmdr1mutations
in a study of only 7 samples from Brazil, while Barnadas et al. (2008) [18] reported 21 muta-
tions among 105 samples fromMadagascar. However, both studies amplified longer fragments
of the Pvmdr1 gene than the present study, which might be a part of the explanation.
Genotyping of microsatellites flanking the Pvmdr1 gene revealed high levels of diversity
around single, double and triple mutant alleles. There were too few wildtype TYF alleles to
meaningfully compare the MS heterozygosity surrounding wildtype and mutant alleles for evi-
dence of selective sweeps on the mutant alleles. However our finding that all 3 wildtype TYF
alleles were flanked by an identical microsatellite haplotype would not support the view that
reduced diversity among microsatellite haplotypes is attributable to selective sweeps, but rather
suggests a tendency to clonal population structure in some populations.
The evidence for association of MS alleles with particular mutations was patchy. TYF and
MYF Pvmdr1 haplotypes occurred together with the “201” m9.5 allele, while the “204” allele at
m9.5 was more commonly seen with MFL and MYL. No obvious pattern of distribution was
seen for the other 3 MS, suggesting this association was caused by greater representation of cer-
tain mutant alleles in particular geographic localities rather than a selective sweep.
The combination of the 5 Pvmdr1 loci into a 5-loci haplotype revealed 57 different haplo-
types among the 125 samples positive at all loci, many of them unique. Country-wise, Nepal
was the most diverse, when analysed by locus and for the combined 5-loci haplotype, whereas
Ecuador was more conserved. The diminished diversity within the Ecuadorian samples is con-
sistent with the general finding of little diversity amongst P. vivax samples from the Americas,
although this is not a hard and fast rule [40]. Just 10 samples of African origin were available
for this study but both double and triple Pvmdr1mutant alleles were present, and their micro-
satellite fingerprint was distinct from that associated with the same alleles in Asia. Likewise,
our South American sample from Ecuador (n = 17) was distinct from the other populations
being less diverse, and unique in having the wild-type Pvmdr1 allele.
Studies of P. falciparum have revealed a contrasting pattern of resistance evolution in which
relatively few resistance mutants emerge but then become globally disseminated. The pattern is
consistent for both CQR [26;41] and high levels of resistance to SP [24;27;42–44]. Hawkins
et al. [28;29] analysed the origin and dissemination of SPR in P. vivax by analysing SNPs in
and surrounding the Pvdhfr and Pvdhps genes. They concluded that the genes are considerably
more diverse than seen in P. falciparum [28;29] and that highly pyrimethamine-resistant
Fig 4. Plasmodium vivax mdr1 combined with flankingmicrosatellite variation in P. vivax samples
collected at 9 malaria endemic districts of Sri Lanka. The size of the pie charts reflects the sample size,
while the segments illustrate the frequency of combined Pvmdr SNP+microsatellite haplotypes. Grey color
segment indicates the proportion of the sample which consisted of unique 'singleton' haplotypes while the
other colors indicate the proportion of each repeated haplotype. The black lines indicate sharing of a specific
haplotype between two sites and multiple lines indicate the number of haplotypes shared between given
sites.
doi:10.1371/journal.pntd.0004196.g004
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Pvdhfr alleles arose three times in Thailand, Indonesia and PNG/Vanuatu, and that sulfadoxine
resistance associated SNPs had evolved independently on multiple occasions. This is consistent
with our findings on Pvmdr and may be explained by comparisons of total genomic diversity
among P. vivax and P. falciparum isolates. A study by Neafsey et al. [45] reported twice as
much SNP diversity, significantly higher MS diversity and a far deeper divergence among P.
vivax geographic isolates than among a comparable set of P. falciparum isolates. The higher
level of diversity in P. vivax can explain the multiple origin pattern of resistance emergence in
of Pvmdr1, Pvdhfr and Pvdhps.
Our findings can indicate three things. First, Pvmdr1mutant alleles have developed on mul-
tiple haplotype backgrounds by convergent evolution in Pakistan, Nepal, Sri Lanka, Ecuador,
Sao Tomé and Sudan. Second, assuming that Pvmdr1 is a reliable CQR marker, there is little
evidence that the variation around mutant haplotypes has been subject to a selective sweep,
(the result of positive natural selection causing diminished diversity in sequences flanking the
selected marker). Third, the historical pattern of drug resistance emergence in P. falciparum is
not repeated in P. vivax. The time-delay of around 30 years between initial reports of CQR in
the two malaria species, and the two different treatment regimens (mono-in P. falciparum and
usually combined CQ/primaquine treatment in P. vivax) might explain this, and may suggest
that it is just a matter of time before the effect of selection of the markers can be seen since high
grade treatment failure has not yet been reported in any of the sites sampled in this study. P.
vivax is generally a chronic disease with low parasitaemia causing mild symptoms compared to
P. falciparum, therefore there is less selective drug pressure on the parasite. Furthermore, the
fast gametocytogenesis in P. vivax enables uptake of gametes by vectors before clinical symp-
toms arise and antimalarial treatment is initiated which balances the spread of sensitive and
resistant P. vivax parasites.
Equally, these differences may lie with the biology and transmission dynamics of the two
species. Our district level analysis of Pvmdr and linked MS variation in Sri Lanka found evi-
dence of exchange of genotypes between districts which may or may not be linked to their
resistance phenotype. Latent P. vivax infections cause relapses of the disease, which may
increase the possibility of migration of parasites within the human host while the broader tem-
perature tolerance by P. vivax parasites compared to P. falciparummight increase the likeli-
hood of gene flow between sites with varying temperature or microclimate.
Finally CQR may be a complex trait including other genes in addition to Pvmdr1 and future
research will hopefully illuminate the genomic-level change underpinning changes in CQ sen-
sitivity. Meanwhile, monitoring and research of CQR is of highest importance for the public
health in the afflicted areas.
Supporting Information
S1 Table. The number of detected alleles per collection site and locus; thePvmdr1 gene and
the four microsatellites m9.5, 10.1, 10.4, and 43.1. The Pvmdr1 alleles are named TYF (wild-
type allele), MYF, MYL and MFL, corresponding to the codes of the amino acids encoded by
the polymorphic codons 958, 976 and 1076, respectively.
(DOCX)
S2 Table. Linkage disequilibrium analysis between Pvmdr1 alleles and alleles of flanking
microsatellites. Significant LD (D' = 1, P< 0.05) between Pvmdr1 alleles (TYF, MTF, MYL,
and MFL) and alleles of each of three flanking microsatellites (MS); m9.5, m10.1, and m10.4.
Significant LD was not found between the Pvmdr1 alleles and m43.1 alleles. LD calculations
were carried out for the total pooled sample (T) and for individual populations in Pakistan,
Nepal, Sri Lanka, Ecuador, Sao Tomé and Sudan. Significant LD could only be detected in
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Ecuador (E), Sri Lanka (SL) and Nepal (N) and in the total sample set (T). In brackets is the
number of alleles in complete LD detected per study site. Excluded in the table are haplotypes
with frequencies >1 and mixed infection samples. Pairwise significance levels are as follows:
“”significance at the 0.1% nominal level, “” significance at the 1% nominal level and “”
significance at the 5% nominal level.
(DOCX)
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